Global Rapid Influenza Diagnostic Test (RIDT) Market Size, Status and Forecast 2022

RIDT Market 

The global Rapid Influenza Diagnostic Test (RIDT) market size is projected to reach USD 2128.5 Million by 2027, from USD 1173.4 Million in 2020, at a CAGR of 9.0% during 2021-2027.

Rapid influenza diagnostic tests (RIDTs) are immunoassays that can identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens, and display the result in a qualitative way (positive vs. negative). In the United States, a number of RIDTs are commercially available. The reference standards for laboratory confirmation of influenza virus infection in respiratory specimens are reverse transcription-polymerase chain reaction (RT-PCR) or viral culture. RIDTs can yield results in a clinically relevant time frame, i.e., less than approximately 15 minutes. However, RIDTs have limited sensitivity to detect influenza viruses in respiratory specimens compared to RT-PCR or viral culture and negative RIDT test results should be interpreted with caution given the potential for false negative results, especially during peak influenza activity in a community. Some RIDTs use analyzer reader devices to standardize result interpretation.

Americas is the largest Rapid Influenza Diagnostic Test (RIDT) market with about 58% market share. Europe is follower, accounting for about 25% market share.

The key players are BD, Abbot (Alere), Quidel, Roche, Thermo Fisher Scientific, Meridian Bioscience, Analytik Jena, Princeton BioMeditech Corporation, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific, DiaSorin (Focus Diagnostics), Wondfo, Beijing Wantai Biological Pharmacy etc. Top 3 companies occupied about 49% market share.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Rapid Influenza Diagnostic Test (RIDT) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Rapid Influenza Diagnostic Test (RIDT) market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Rapid Influenza Diagnostic Test (RIDT) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Rapid Influenza Diagnostic Test (RIDT) market.

Rapid Influenza Diagnostic Test (RIDT) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Rapid Influenza Diagnostic Test (RIDT) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. 

By Type

• Digital RIDTs
• Conventional RIDT

By Application

• Hospitals
• POCT
• Others 

By Region

• North America
• US.
• Canada
• Europe
• Germany
• France
• UK.
• Italy
• Russia
• Nordic
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA 

Key Companies

• BD
• Abbot (Alere)
• Quidel
• Roche
• Thermo Fisher Scientific
• Meridian Bioscience
• Analytik Jena
• Princeton BioMeditech Corporation
• BioMerieux
• Sekisui Diagnostics
• Response Biomedical
• SA Scientific
• DiaSorin (Focus Diagnostics)
• Wondfo
• Beijing Wantai Biological Pharmacy